Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Hemodialysis Patients (DAPA-HD)
NCT05179668Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Oct 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in left ventricular hypertrophy (LVH), kidney failure (ESRD), sponsored by Medical University of Vienna. Started Oct 2022; status: completed.
02
Drugs
dapagliflozin
03
Conditions
left ventricular hypertrophy (LVH)kidney failure (ESRD)
Beyond the preview
Go deeper on NCT05179668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179668.